Literature DB >> 16870221

Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.

R G A Jones1, T-A Alsop, R Hull, R Tierney, P Rigsby, J Holley, D Sesardic.   

Abstract

In this study, we have compared two in vivo assay methods to measure the type A botulinum toxin neutralising activity of specific immunoglobulin G (IgG) and its fragments (F(ab')(2), Fab', Fab) purified from pentavalent botulinum antisera raised in goats. Each assay method was repeated on three separate occasions in mice and relative potencies calculated with respect to a type A equine reference antitoxin. The conventional assay, which measures the number of mice surviving typically after 72 or 96 h following the intraperitoneal administration of a mixture of toxin and antitoxin, gave the following order of potency IgG>F(ab')(2)>Fab'>Fab (6.8>4.7>3.5>2.6 IU/mg). Differences in potency are likely to be due to differences in the pharmacokinetics of the antitoxins, which are related to their molecular weight. The alternative local flaccid paralysis assay, where toxin and antitoxin are injected subcutaneously into the left inguinocrural region, gave results with a narrower range of activities: IgG>Fab'>F(ab')(2)>Fab (6.0>5.9>5.5>4.6 IU/mg). Comparison of the two assay methods showed no significant differences for IgG, F(ab')(2) or Fab', although the Fab fragment was significantly more potent in the non-lethal assay probably because of the reduced influence of antitoxin pharmacokinetics in this localised assay. These findings show that a local flaccid paralysis assay provides a less time consuming and more humane alternative to the lethal assay for the potency testing of botulinum IgG and F(ab')(2) antitoxins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870221     DOI: 10.1016/j.toxicon.2006.05.007

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  11 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

2.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

3.  Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Yun-Yun Mao; Rong-Tian Cui; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Jie Dong; Zhi-Xin Yang; Zhi-Wei Sun; Xiao-Bin Pang
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

Review 4.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments.

Authors:  Anastasiya Yermakova; Nicholas J Mantis
Journal:  Toxicon       Date:  2013-04-17       Impact factor: 3.033

6.  Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations.

Authors:  Amram Torgeman; Eyal Ozeri; Alon Ben David; Eran Diamant; Osnat Rosen; Arieh Schwartz; Ada Barnea; Arik Makovitzki; Avishai Mimran; Ran Zichel
Journal:  Toxins (Basel)       Date:  2017-05-29       Impact factor: 4.546

7.  Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.

Authors:  Sebastian Miethe; Christelle Mazuet; Yvonne Liu; Robert Tierney; Christine Rasetti-Escargueil; Arnaud Avril; André Frenzel; Philippe Thullier; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Dorothea Sesardic; Michael Hust; Michel Robert Popoff
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

8.  Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.

Authors:  Christine Rasetti-Escargueil; Arnaud Avril; Siham Chahboun; Rob Tierney; Nicola Bak; Sebastian Miethe; Christelle Mazuet; Michel R Popoff; Philippe Thullier; Michael Hust; Thibaut Pelat; Dorothea Sesardic
Journal:  MAbs       Date:  2015-09-18       Impact factor: 5.857

9.  Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.

Authors:  Yağmur Derman; Katja Selby; Sebastian Miethe; André Frenzel; Yvonne Liu; Christine Rasetti-Escargueil; Arnaud Avril; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Philippe Thullier; Dorothea Sesardic; Miia Lindström; Michael Hust; Hannu Korkeala
Journal:  Toxins (Basel)       Date:  2016-09-12       Impact factor: 4.546

10.  SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.

Authors:  Nicola Bak; Shalini Rajagopal; Paul Stickings; Dorothea Sesardic
Journal:  Toxins (Basel)       Date:  2017-07-20       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.